Vaccinex, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vaccinex, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $2.00K, a 99.90% decline year-over-year.
- Vaccinex, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $1.35M.
- Vaccinex, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $4.11M.
- Vaccinex, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $2.04M, a 84.58% decline year-over-year.
- Vaccinex, Inc. stock issued during period, value, new issues for fiscal 2023 was $1.28M, a 92.50% decline from fiscal 2022.
- Vaccinex, Inc. stock issued during period, value, new issues for fiscal 2022 was $17.05M, a 48.09% decline from fiscal 2021.
- Vaccinex, Inc. stock issued during period, value, new issues for fiscal 2021 was $32.85M, a 15.36% increase from fiscal 2020.
- Vaccinex, Inc. stock issued during period, value, new issues for fiscal 2020 was $28.48M, a 106.34% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-03-31 | $2.00K 10-Q · filed 2024-11-14 | |
| 2023-12-31 | $1.28M 10-K/A · filed 2024-04-25 | |
| 2023-09-30 | $1.35M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $4.11M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $2.04M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $17.05M 10-K · filed 2023-03-31 | |
| 2022-03-31 | $13.23M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $32.85M 10-K · filed 2023-03-31 | |
| 2021-03-31 | $32.85M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $28.48M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $18.65M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $2.30M 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $7.48M 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $13.80M 10-K · filed 2021-03-31 | |
| 2019-09-30 | $13.80M 10-Q · filed 2020-11-13 |